Welcome to our dedicated page for Maxcyte news (Ticker: MXCT), a resource for investors and traders seeking the latest updates and insights on Maxcyte stock.
MaxCyte, Inc. reports news on its cell-engineering technology business for biotechnology and pharmaceutical customers developing next-generation cell therapeutics. Company updates center on Flow Electroporation technology, ExPERT instruments, SeQure gene editing assessment services, and Strategic Platform License relationships that can generate product, license, research, clinical and program-related revenue.
Recurring developments include quarterly and annual financial results, revenue guidance, installed instrument activity, licensed customer programs, product launches such as ExPERT DTx for high-throughput electroporation, and corporate governance matters including executive appointments and equity compensation grants.
MaxCyte (Nasdaq: MXCT) announced a technology license partnership with Genentech, a member of the Roche Group, to support development of cell therapy programs. The agreement provides Genentech access to MaxCyte’s ExPERT GTx platform and additional platform technologies across select research, clinical development, and manufacturing workflows.
The multi-program license is designed to enable ex vivo cell engineering applications and streamline progression from early discovery through cGMP manufacturing. According to MaxCyte, the collaboration brings together complementary capabilities in cell engineering, gene editing, and analytical workflows to support next-generation cell-based therapeutics throughout the development lifecycle.
MaxCyte (NASDAQ: MXCT) will release its second quarter 2026 financial results after the U.S. market close on Wednesday, August 12, 2026. Company management will host an earnings conference call at 4:30 p.m. Eastern Time, with live and archived webcast access via the Events section of its investor website.
MaxCyte (NASDAQ: MXCT) reported Q1 2026 revenue of $9.7 million, down 7% year over year, with core revenue of $6.2 million and SPL Program-related revenue of $3.4 million. Net loss improved to $4.8 million from $10.3 million and cash totaled $147.7 million.
The company reiterated 2026 revenue guidance of $30–32 million, including core revenue of $25–27 million and about $5 million of SPL revenue. The board also authorized a $10 million share repurchase program over the next year.
MaxCyte (NASDAQ: MXCT) will release first quarter 2026 financial results after the U.S. market close on May 12, 2026. Company management will host a conference call at 4:30 p.m. Eastern Time. Investors must register online in advance. A live and archived webcast will be available on the Events section of the MaxCyte investor website at https://investors.maxcyte.com/.
MaxCyte (Nasdaq: MXCT) granted inducement awards tied to the appointment of Parmeet Ahuja as Chief Financial Officer. The Compensation Committee approved stock options for 375,000 shares (10-year term, exercise price $0.676) and 187,500 RSUs.
Grant dates: stock options March 30, 2026; RSUs April 15, 2026. Options vest 25% after one year then monthly over 36 months; RSUs vest 25% after one year then in three equal annual installments, each subject to continued service. Disclosed under Nasdaq Listing Rule 5635(c)(4).
MaxCyte (NASDAQ: MXCT) reported Q4 2025 revenue $7.3M and FY2025 revenue $33.0M, down 16% and 15% year-over-year respectively. Gross margin for FY2025 was 81%. Cash, cash equivalents and investments were $155.6M at year-end; company expects at least $136M at end of 2026. 2026 revenue guidance: $30–32M (Core $25–27M; SPL ~ $5M).
The company cited a 15% reduction in purchases from its largest SPL customer impacting 2025 and expects stabilization and later growth in H2 2026.
MaxCyte (Nasdaq: MXCT) appointed Parmeet Ahuja as Chief Financial Officer, effective March 30, 2026. Mr. Ahuja succeeds Douglas Swirsky, whose transition was previously announced in November 2025. Mr. Ahuja brings over 20 years of finance leadership at Agilent, including investor relations and FP&A roles.
The company said he will strengthen financial operations, support disciplined execution, and help advance strategic priorities for its electroporation platform in cell and gene therapy.
MaxCyte (NASDAQ: MXCT) launched ExPERT DTx™, a 96-well high-throughput electroporation platform for research and drug discovery on Feb 24, 2026. The modular system processes up to 96 samples in a single three-minute run with the R-50x96™ assembly and 12 detachable 8-well strips.
The platform emphasizes low cellular stress, consistent well-to-well performance, validated applications from cell and gene therapy to protein production, and software enabling remote experiment design and easy transfer to other ExPERT instruments for scale-up into cGMP workflows.
MaxCyte (NASDAQ: MXCT) will release fourth quarter and full year 2025 financial results after U.S. market close on March 24, 2026. Management will host a conference call at 4:30 p.m. ET the same day to discuss results.
Investors must register online to join the call; a live and archived webcast will be available in the company’s Events section at the investor website.
MaxCyte (Nasdaq: MXCT) provided preliminary unaudited results for the quarter and year ended December 31, 2025. Q4 core revenue is expected to be $6.6M–$6.7M and FY2025 core revenue is expected to be $29.5M–$29.6M. SPL program revenue is expected to be $0.4M–$0.6M for Q4 and $3.3M–$3.5M for FY2025. Cash, cash equivalents, and investments are expected to be approximately $155.6M as of December 31, 2025. Management described 2025 as challenging but said core revenue was in line with guidance, noted cost-structure improvements and program rationalization, and stated an expectation to return to revenue growth in H2 2026. Final audited results are expected in March 2026.